Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose
MG Bruce, D Bruden, D Hurlburt, C Zanis… - The Journal of …, 2016 - academic.oup.com
MG Bruce, D Bruden, D Hurlburt, C Zanis, G Thompson, L Rea, M Toomey…
The Journal of infectious diseases, 2016•academic.oup.comBackground. The duration of protection in children and adults resulting from hepatitis B
vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and
children from 15 Alaska communities aged≥ 6 months using 3 doses of plasma-derived
hepatitis B vaccine. Methods. Persons were tested for antibody to hepatitis B surface antigen
(anti-HBs) levels 30 years after receiving the primary series. Those with levels< 10 mIU/mL
received 1 booster dose of recombinant hepatitis B vaccine 2–4 weeks later and were then …
vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and
children from 15 Alaska communities aged≥ 6 months using 3 doses of plasma-derived
hepatitis B vaccine. Methods. Persons were tested for antibody to hepatitis B surface antigen
(anti-HBs) levels 30 years after receiving the primary series. Those with levels< 10 mIU/mL
received 1 booster dose of recombinant hepatitis B vaccine 2–4 weeks later and were then …
Abstract
Background. The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized a cohort of 1578 Alaska Native adults and children from 15 Alaska communities aged ≥6 months using 3 doses of plasma-derived hepatitis B vaccine.
Methods. Persons were tested for antibody to hepatitis B surface antigen (anti-HBs) levels 30 years after receiving the primary series. Those with levels <10 mIU/mL received 1 booster dose of recombinant hepatitis B vaccine 2–4 weeks later and were then evaluated on the basis of anti-HBs measurements 30 days after the booster.
Results. Among 243 persons (56%) who responded to the original primary series but received no subsequent doses during the 30-year period, 125 (51%) had an anti-HBs level ≥10 mIU/mL. Among participants with anti-HBs levels <10 mIU/mL who were available for follow-up, 75 of 85 (88%) responded to a booster dose with an anti-HBs level ≥10 mIU/mL at 30 days. Initial anti-HBs level after the primary series was correlated with higher anti-HBs levels at 30 years.
Conclusions. Based on anti-HBs level ≥10 mIU/mL at 30 years and an 88% booster dose response, we estimate that ≥90% of participants had evidence of protection 30 years later. Booster doses are not needed.
Oxford University Press